News

GTI may help ID who’s at risk for glucocorticoid side effects

ANCA-associated vasculitis (AAV) patients receiving a cumulative dose of at least 935 mg of glucocorticoids over six months are more likely to see clinically meaningful side effects, according to a study using calculations based on the Glucocorticoid Toxicity Index (GTI). The findings suggest the GTI, which considers the frequency…

Clinical trial recruitment for povetacicept ongoing in 3 countries

Recruitment is continuing in three countries for a Phase 1b/2a clinical trial testing Alpine Immune Sciences’ povetacicept in adults with autoimmune conditions affecting the kidneys, including ANCA-associated vasculitis (AAV). Called RUBY-3 (NCT05732402), the early study is designed to enroll an estimated 56 patients, ages 18 and older,…

Renal Risk Score a better predictor of long-term kidney function

The Renal Risk Score may be a better histopathologic classification model than Berden for predicting long-term loss of kidney function in people with ANCA-related vasculitis (AAV) who have glomerulonephritis, an inflammation of the kidneys’ filtering units, a study finds. Incorporating the renal risk score into clinical decision-making could help…

Urine, blood biomarkers may help track AAV activity: Study

Biomarkers measured in blood or urine may help track disease activity and organ damage in people with ANCA-associated vasculitis (AAV), according to a systematic review study. AAV is an autoimmune disorder in which self-reactive antibodies called anti-neutrophil cytoplasmic antibodies (ANCAs) attack the body’s own neutrophils — a type of…

In EGPA, Fasenra outperforms Nucala at reducing steroid use

Fasenra (benralizumab), which is approved for a rare type of asthma, and Nucala (mepolizumab) were similarly effective at inducing remission in eosinophilic granulomatosis with polyangiitis (EGPA), but more people on Fasenra were able to stop using oral corticosteroids (OCS), with fewer monthly injections. That’s according to final published…